Detailed company information
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Last Updated: Sep 2026
Earnings Transcript for 2026 - Q2Released: Aug 12, 2026
Earnings Transcript for 2026 - Q1Released: May 11, 2026
Earnings Transcript for 2025 - Q4Released: Mar 05, 2026
Earnings Transcript for 2025 - Q3Released: Nov 03, 2025
Earnings Transcript for 2025 - Q2Released: Aug 12, 2025
Earnings Transcript for 2025 - Q1Released: May 10, 2025
Earnings Transcript for 2024 - Q4Released: Mar 19, 2025
Earnings Transcript for 2024 - Q3Released: Nov 13, 2024
Earnings Transcript for 2024 - Q2Released: Aug 08, 2024
Earnings Transcript for 2024 - Q1Released: May 14, 2024
Earnings Transcript for 2023 - Q4Released: Mar 13, 2024
Earnings Transcript for 2023 - Q3Released: Nov 07, 2023
Earnings Transcript for 2023 - Q2Released: Aug 10, 2023
Earnings Transcript for 2023 - Q1Released: May 06, 2023
Earnings Transcript for 2022 - Q4Released: Mar 16, 2023
Earnings Transcript for 2022 - Q3Released: Nov 08, 2022
Earnings Transcript for 2022 - Q2Released: Aug 11, 2022
Earnings Transcript for 2022 - Q1Released: May 12, 2022
Earnings Transcript for 2021 - Q4Released: Mar 17, 2022
Earnings Transcript for 2021 - Q2Released: Aug 10, 2021
Earnings Transcript for 2021 - Q1Released: May 13, 2021
Earnings Transcript for 2020 - Q4Released: Mar 23, 2021
Earnings Transcript for 2020 - Q3Released: Nov 09, 2020
Earnings Transcript for 2020 - Q2Released: Aug 10, 2020
GOSS Gossamer Bio, Inc.
Liquidia Corporation reported a steady rise in monthly active patients and a stable average revenue per patient (ARPP) for Q4 2025 through early 2026. The data indicates strong patient growth momentum and consistent revenue generation during this period.
Read post
Dafinchi
